Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$1.32 USD
+0.03 (2.33%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.33 +0.01 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
OCUP 1.32 +0.03(2.33%)
Will OCUP be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for OCUP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCUP
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
OCUP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Other News for OCUP
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Ocuphire Pharma announces publication of Phase 3 results of RYZUMVI
UPDATE ? Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Ocuphire Pharma initiates VEGA-3 Phase 3 trial